Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

Molecular Oncology

Volumn 9, Issue 7, 2015, Pages 1371-1383

  Stanam, Aditya ^a,b   Love Homan, Laurie ^b   Joseph, Tisha S ^c   Espinosa Cotton, Madelyn ^b   Simons, Andrean L ^a,b,d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c LINCOLN UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

EGFR; Erlotinib; HNSCC; IL 6; Resistance; Tocilizumab

Indexed keywords

ERLOTINIB; INTERLEUKIN 6; TOCILIZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; GENETICS; HEAD AND NECK TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERLOTINIB HYDROCHLORIDE; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 84938196475     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.03.008     Document Type: Article

References (23)

1. Argiris A., Kotsakis A.P., Hoang T., Worden F.P., Savvides P., Gibson M.K., Gyanchandani R., Blumenschein G.R., Chen H.X., Grandis J.R., Harari P.M., Kies M.S., Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 2013, 24:220-225.
2. Bei R., Budillon A., Masuelli L., Cereda V., Vitolo D., Di Gennaro E., Ripavecchia V., Palumbo C., Ionna F., Losito S., Modesti A., Kraus M.H., Muraro R. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J. Pathol. 2004, 204:317-325.
3. Cohen E.E., Kane M.A., List M.A., Brockstein B.E., Mehrotra B., Huo D., Mauer A.M., Pierce C., Dekker A., Vokes E.E. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11:8418-8424.
4. de Souza J.A., Davis D.W., Zhang Y., Khattri A., Seiwert T.Y., Aktolga S., Wong S.J., Kozloff M.F., Nattam S., Lingen M.W., Kunnavakkam R., Stenson K.M., Blair E.A., Bozeman J., Dancey J.E., Vokes E.E., Cohen E.E. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2012, 18:2336-2343.
5. Duffy S.A., Taylor J.M., Terrell J.E., Islam M., Li Y., Fowler K.E., Wolf G.T., Teknos T.N. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008, 113:750-757.
6. Fletcher E.V., Love-Homan L., Sobhakumari A., Feddersen C.R., Koch A.T., Goel A., Simons A.L. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol. Cancer Res. 2013, 11:1574-1584.
7. Giles K.M., Kalinowski F.C., Candy P.A., Epis M.R., Zhang P.M., Redfern A.D., Stuart L.M., Goodall G.J., Leedman P.J. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 2013, 12:2541-2558.
8. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012, 38:904-910.
9. Heimdal J.H., Kross K., Klementsen B., Olofsson J., Aarstad H.J. Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma. BMC Cancer 2008, 8:34.
10. Kamimura D., Ishihara K., Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 2003, 149:1-38.
11. Krysan K., Cui X., Gardner B.K., Reckamp K.L., Wang X., Hong L., Walser T.C., Rodriguez N.L., Pagano P.C., Garon E.B., Brothers J.F ll, Elashoff D., Lee J.M., Spira A.E., Sharma S., Fishbein M.C., Dubinett S.M. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am. J. Transl. Res. 2013, 5:481-496.
12. Li L., Han R., Xiao H., Lin C., Wang Y., Liu H., Li K., Chen H., Sun F., Yang Z., Jiang J., He Y. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res. 2014, 20:2714-2726.
13. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond) 2012, 122:143-159.
14. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., Zhou C., Su W.C., Wang M., Sun Y., Heo D.S., Crino L., Tan E.H., Chao T.Y., Shahidi M., Cong X.J., Lorence R.M., Yang J.C. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012, 13:528-538.
15. Rexer B.N., Engelman J.A., Arteaga C.L. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009, 8:18-22.
16. Riedel F., Zaiss I., Herzog D., Gotte K., Naim R., Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 2005, 25:2761-2765.
17. Ross H.J., Blumenschein G.R., Aisner J., Damjanov N., Dowlati A., Garst J., Rigas J.R., Smylie M., Hassani H., Allen K.E., Leopold L., Zaks T.Z., Shepherd F.A. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 2010, 16:1938-1949.
18. Shinriki S., Jono H., Ota K., Ueda M., Kudo M., Ota T., Oike Y., Endo M., Ibusuki M., Hiraki A., Nakayama H., Yoshitake Y., Shinohara M., Ando Y. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin. Cancer Res. 2009, 15:5426-5434.
19. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004, 22:77-85.
20. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., Knecht R., Amellal N., Schueler A., Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007, 25:2171-2177.
21. Weichselbaum R.R., Dahlberg W., Beckett M., Karrison T., Miller D., Clark J., Ervin T.J. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2684-2688.
22. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 2007, 21:1396-1408.
23. Yao Z., Fenoglio S., Gao D.C., Camiolo M., Stiles B., Lindsted T., Schlederer M., Johns C., Altorki N., Mittal V., Kenner L., Sordella R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15535-15540.